A doctor's job is TrendPulse Quantitative Think Tank Centerto help patients. With that, very often comes lots and lots of paperwork. That's where some startups are betting artificial intelligence may come in.
NPR science correspondent Geoff Brumfiel has been looking into the use of AI in the medical field and he brings us an age old question: Do the benefits outweigh the risks?
Dereck Paul hopes the answer is yes. He's a co-founder of the startup Glass Health. Dereck was an early skeptic of chatbots. "I looked at it and I thought it was going to write some bad blog posts ... who cares?" But now, he's excited about their experimental feature Glass AI 2.0. With it, doctors can enter a short patient summary and the AI sends back an initial clinical plan, including potential tests and treatments, Dereck says. The goal is to give doctors back time they would otherwise use for routine tasks.
But some experts worry the bias that already exists in the medical system will be translated into AI programs. AI "has the sheen of objectivity. 'ChatGPT said that you shouldn't have this medication — it's not me,'" says Marzyeh Ghassemi, a computer scientist studying AI and health care at MIT. And early independent research shows that as of now, it might just be a sheen.
So the age old answer to whether the benefits outweigh the risks seems to be ... time will tell.
Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts.
Have a lead on AI in innovative spaces? Email us at [email protected]!
This episode was produced by Berly McCoy, edited by Rebecca Ramirez and fact checked by Nicolette Khan. The audio engineer was Robert Rodriguez.
2025-05-03 08:54861 view
2025-05-03 08:342887 view
2025-05-03 08:132966 view
2025-05-03 07:372301 view
2025-05-03 06:19444 view
2025-05-03 06:171086 view
PROVIDENCE, R.I. (AP) — Cybercriminals could release personal data of many Rhode Islanders as early
NEW YORK (AP) — Martin Scorsese has spent a sizeable portion of his life talking about movies he lov
Macy’s is terminating its monthslong buyout talks with two investment firms, citing a substandard of